Drug intelligence / Profile preview

EC-17

Development stage: Phase 2
Lead developer: Novartis
Modality: Small Molecules
Administration: Intravenous

Overview

EC-17, also known as Folate-FITC, is a conjugate of fluorescein isothiocyanate (FITC) and folate. It has potential antineoplastic activity by binding to folate receptors, which are overexpressed on many cancer cells, including ovarian and kidney cancer cells. This binding allows circulating anti-fluorescein antibodies to recognize and bind to the FITC moiety, leading to antibody-dependent cellular cytotoxicity. EC-17 is used in trials for diagnosing ovarian cancer and has been explored in phase II clinical trials for various cancers.

Other names: Folate-FITCFolate-fluorescein conjugate

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on EC-17.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EC-17.

Explore the full profile